Journal
VACCINE
Volume 30, Issue -, Pages F168-F174Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2012.06.045
Keywords
HPV; HIV; Immunosuppression; Cervical cancer prevention; HPV vaccination; Anal cancer; Perinatal transmission; Male circumcision
Categories
Funding
- Bill and Melinda Gates Foundation, USA [35537]
- European Commission [HEALTH-F3-2010-242061]
- Instituto de Salud Carlos III (Spanish Government) [FIS PI10/02995, RCESP C03/09, RTICESP C03/10, RTIC RD06/0020/0095, CIBERESP]
- Agencia de Gestio d'Ajuts Universitaris i de Recerca - Generalitat de Catalunya (Catalonian Government) [AGAUR 2005SGR00695, AGAUR 2009SGR126]
- GlaxoSmithKline
- Merck and Co.
- Sanofi Pasteur MSD
- Qiagen
Ask authors/readers for more resources
The vast majority of women infected with human immunodeficiency virus (HIV) will be co-infected with human papillomavirus (HPV). The interaction between the two sexually transmitted infections appears to be related to the alteration in cell-mediated immunity in HIV infected persons, increased susceptibility, and possibly reactivation of latent HPV infection. Linkage studies of HIV/AIDs and Cancer registries have indicated a 2- to 22-fold increase in cervical cancer in HIV-positive women compared to HIV-negative women. Data on the prevalence of HPV types in invasive cervical carcinoma (ICC) suggest that the proportion of infection with types HPV16/18 (responsible for over 70% of all cervical cancers) is similar in HIV-negative and HIV-positive women. The biological interaction between HIV and HPV needs further elucidation, although there is some evidence that the presence of HPV infection may be associated with increased HIV transmission. Adolescents perinatally infected by HIV are known to have higher rates of HPV infection and also have been shown to seroconvert in response to HPV vaccination with the quadrivalent vaccine, albeit to lower titers than HIV-negative individuals. Anal cancer incidence is greatly increased in HIV-positive individuals, particularly in HIV-positive men who have sex with men. Screening for anal cancer precursors is feasible and effective; however, the impact on reduction of anal cancer remains to be demonstrated. There are ongoing studies on the safety, immunogenicity, and efficacy of current HPV vaccines in HIV-positive individuals and mature data are awaited. Male circumcision may be another approach to prevention of HPV transmission, which also requires further study. This article forms part of a special supplement entitled Comprehensive Control of HPV Infections and Related Diseases Vaccine Volume 30, Supplement 5, 2012. (C) 2012 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available